Details of the Drug

General Information of Drug (ID: DMCFLRH)

• Drug Name: Cibinetide
• Synonyms: UNII-9W5677JKDA; 9W5677JKDA; 1208243-50-8; Cibinetide [USAN]; Pglu-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser; Pyr-glu-gln-leu-glu-arg-ala-leu-asn-ser-ser-OH; GTPL9677; CHEMBL3545305; DB13006; L-Serine, 5-oxo-L-prolyl-L-alpha-glutamyl-L-glutaminyl-L-leucyl-L-alpha-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-; L-Pyroglutamyl-L-glutamyl-L-glutaminyl-L-leucyl-L-glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyl-L-seryl-L-serine; L-Pyroglutamyl-L-glutamyl-L-glutam

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Phase 2	[1]
Neuropathic pain	8E43.0	Phase 2	[2]
Sarcoidosis	4B20.5	Phase 2	[3]
Diabetic macular edema	9B71.02	Phase 1	[4]
Peripheral neuropathy	8C0Z	Phase 1	[5]

• #Ro5 Violations (Lipinski): 5:
  Molecular Weight (mw); 1257.3
  Logarithm of the Partition Coefficient (xlogp); -7.7
  Rotatable Bond Count (rotbonds); 42
  Hydrogen Bond Donor Count (hbonddonor); 20
  Hydrogen Bond Acceptor Count (hbondacc); 22
• Chemical Identifiers:
  Formula: C51H84N16O21
  IUPAC Name: (4S)-5-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-oxo-4-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]pentanoic acid
  Canonical SMILES: C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCC(=O)N1
  InChI: InChI=1S/C51H84N16O21/c1-22(2)17-30(47(84)65-32(19-36(53)71)48(85)66-33(20-68)49(86)67-34(21-69)50(87)88)63-40(77)24(5)57-41(78)25(7-6-16-56-51(54)55)59-43(80)29(11-15-39(75)76)62-46(83)31(18-23(3)4)64-45(82)27(8-12-35(52)70)60-44(81)28(10-14-38(73)74)61-42(79)26-9-13-37(72)58-26/h22-34,68-69H,6-21H2,1-5H3,(H2,52,70)(H2,53,71)(H,57,78)(H,58,72)(H,59,80)(H,60,81)(H,61,79)(H,62,83)(H,63,77)(H,64,82)(H,65,84)(H,66,85)(H,67,86)(H,73,74)(H,75,76)(H,87,88)(H4,54,55,56)/t24-,25-,26-,27-,28-,29-,30-,31-,32-,33-,34-/m0/s1
  InChIKey: WZTIQQBMSJTRBR-WYKNNRPVSA-N
• Cross-matching ID:
  PubChem CID: 91810664
  CAS Number: 1208243-50-8
  UNII: 9W5677JKDA
  DrugBank ID: DB13006
  TTD ID: D0F5AR
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erythropoietin Receptor (EPOR)	TTAUX24	EPOR_HUMAN	Agonist	[5]

Molecular Expression Atlas of This Drug

• The Studied Disease: Depression
• ICD Disease Classification: 6A70-6A7Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Erythropoietin Receptor (EPOR)	DTT	EPOR	7.04E-01	0.11	0.27

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035038)
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)